Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
R-01 by Hangzhou Neoantigen Therapeutics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
R-01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According...
R-01 by Hangzhou Neoantigen Therapeutics for Metastatic Pancreatic Cancer: Likelihood of Approval
R-01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Metastatic Pancreatic Cancer. According to...
R-01 by Hangzhou Neoantigen Therapeutics for Gastrointestinal Tract Cancer: Likelihood of Approval
R-01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Gastrointestinal Tract Cancer. According to...
R-01 by Hangzhou Neoantigen Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
R-01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to...
R-01 by Hangzhou Neoantigen Therapeutics for Metastatic Bile Duct Cancer: Likelihood of Approval
R-01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Metastatic Bile Duct Cancer. According...
R-01 by Hangzhou Neoantigen Therapeutics for Gastric Cancer: Likelihood of Approval
R-01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData,...